{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T01:16:48Z","timestamp":1776302208823,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T00:00:00Z","timestamp":1640131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> The elderly are vulnerable to cardiovascular diseases and the incidence of atrial fibrillation (AF) and venous thromboembolism (VTE) increases significantly with age. Dabigatran is a commonly used new oral anticoagulant approved by the FDA for stroke prevention in patients with non-valvular AF and VTE treatment and prevention. Aspirin is commonly used as a preventive drug for cardiovascular diseases. AF and coronary heart disease share many risk factors, so these two diseases often coexist and thus dabigatran and aspirin are often combined in those people. The aim of this study was to analyze the clinical characteristics of fatal adverse events of dabigatran combined with aspirin in elderly patients, and to provide references for clinical rational use of drugs.<\/jats:p><jats:p><jats:bold>Materials and Methods:<\/jats:bold> Fatal adverse events related to the combined use of dabigatran and aspirin in elderly patients aged over 75 were extracted from the WHO global database of individual case safety reports (VigiBase). Well-documented reports, vigiGrade completeness score \u22650.80, or with an informative narrative, were analyzed with a focus on the clinical features of the cases.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> From 1968 up to January 19, 2020, there were 112 eligible reports in VigiBase from 13 countries, of which 33 were identified as well-documented. Of these 33, 19 were male (58%) and 14 were female (42%), the average age of the patients was 84 (75\u201395\u00a0years), with five cases of extreme weights (&amp;gt;100\u00a0kg in one case, &amp;lt;50\u00a0kg in four cases). There were 31 cases of death by internal bleeding (mainly 15 of gastrointestinal hemorrhage and 12 of intracranial hemorrhage) and two cases of the sudden death of unknown cause. Medication errors existed in 15 patients. The times to onset (TTO) was provided in 24 cases, ranging from 2\u00a0days to 4\u00a0years, and in 12 patients occurred within a month. Of the 31 patients with fatal bleeding events, 29 were associated with other factors that increase the risk of bleeding, such as diseases (hypertension, renal impairment, stroke, gastrointestinal related diseases, hypothyroidism, and cancer), drugs (antiplatelets, anticoagulants, thrombolytics, P glycoprotein substrates, non-steroidal anti-inflammatory drugs, hormones, selective serotonin reuptake inhibitors, and acetaminophen) and other factors (low body weights and alcohol consumption), and 21 of these contained two or more risk factors.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The fatal adverse events associated with the combined use of dabigatran and aspirin in elderly patients were mainly serious bleeding events, which often occurred within 1\u00a0month. Most of these cases had medication errors and most of the patients had multiple diseases, medications, or other conditions at the same time that increase the risk of bleeding. It is suggested that prescription of dabigatran and aspirin in elderly patients should go along with alertness for medication errors, care for correct dose or control of other bleeding risk factors, and the combined medication time should be as short as possible to minimise serious adverse events.<\/jats:p>","DOI":"10.3389\/fphar.2021.769251","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T08:39:01Z","timestamp":1640162341000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Fatal Adverse Events of Dabigatran Combined With Aspirin in Elderly Patients: An Analysis Using Data From VigiBase"],"prefix":"10.3389","volume":"12","author":[{"given":"Qingxia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun-Ying","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2020.11.014","article-title":"Gastroprotection in Patients on Antiplatelet And\/or Anticoagulant Therapy: a Position Paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO)","volume":"85","author":"Abrignani","year":"2021","journal-title":"Eur. J. Intern. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC Guideline for the Management of Patients with Non-ST-elevation Acute Coronary Syndromes: a Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/eurheartj\/eht375","article-title":"Working Group on Thrombosis of the European Society of CardiologyExpert Position Paper on the Role of Platelet Function Testing in Patients Undergoing Percutaneous Coronary Intervention","volume":"35","author":"Aradi","year":"2014","journal-title":"Eur. Heart J. Jan"},{"key":"B4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","article-title":"vigiGrade: a Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues","volume":"37","author":"Bergvall","year":"2014","journal-title":"Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10840-014-9930-y","article-title":"Performance of the HAS-BLED High Bleeding-Risk Category, Compared to ATRIA and HEMORR2HAGES in Patients with Atrial Fibrillation: a Systematic Review and Meta-Analysis","volume":"40","author":"Caldeira","year":"2014","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.2174\/1570161117666190513105859","article-title":"Antiplatelet Therapy in Acute Coronary Syndromes. Lights and Shadows of Platelet Function Tests to Guide the Best Therapeutic Approach","volume":"18","author":"Cimmino","year":"2020","journal-title":"Curr. Vasc. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3390\/medicina57050444","article-title":"Percutaneous Left Atrial Appendage Occlusion: An Emerging Option in Patients with Atrial Fibrillation at High Risk of Bleeding","volume":"57","author":"Cimmino","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1111\/jgs.16062","article-title":"Rate or Rhythm Control in Older Atrial Fibrillation Patients: Risk of Fall-Related Injuries and Syncope","volume":"67","author":"Dalgaard","year":"2019","journal-title":"J. Am. Geriatr. Soc."},{"key":"B41","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cgh.2016.10.011","article-title":"Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation","volume":"15","author":"Flack","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of Diagnosed Atrial Fibrillation in Adults: National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0202575","DOI":"10.1371\/journal.pone.0202575","article-title":"Risk of Intracranial Hemorrhage (RICH) in Users of Oral Antithrombotic Drugs: Nationwide Pharmacoepidemiological Study","volume":"13","author":"Gulati","year":"2018","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1212\/WNL.0b013e318271f848","article-title":"Selective Serotonin Reuptake Inhibitors and Brain Hemorrhage: a Meta-Analysis","volume":"79","author":"Hackam","year":"2012","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","article-title":"The Epidemiology of Venous Thromboembolism","volume":"41","author":"Heit","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCULATIONAHA.110.009035","article-title":"Absolute and Attributable Risks of Atrial Fibrillation in Relation to Optimal and Borderline Risk Factors: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"123","author":"Huxley","year":"2011","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cgh.2014.06.021","article-title":"Use of Selective Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Bleeding: a Systematic Review and Meta-Analysis","volume":"13","author":"Jiang","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3109\/15563650.2012.705290","article-title":"Fatal Gastrointestinal Hemorrhage after a Single Dose of Dabigatran","volume":"50","author":"Kernan","year":"2012","journal-title":"Clin. Toxicol. (Phila)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/fca-2017-0063","article-title":"Bleeding with Oral Anticoagulant Dabigatran Is Highly Associated with Occult Cancers in Atrial Fibrillation Patients","volume":"14","author":"Koike","year":"2018","journal-title":"Future Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e24964","DOI":"10.1371\/journal.pone.0024964","article-title":"Incidence and Severity of Coronary Artery Disease in Patients with Atrial Fibrillation Undergoing First-Time Coronary Angiography","volume":"6","author":"Kralev","year":"2011","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.jacc.2019.08.1031","article-title":"Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week","volume":"74","author":"Kumar","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach: the Euro Heart Survey on Atrial Fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"B21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.11909\/j.issn.1671-5411.2020.01.004","article-title":"Is Dual Therapy the Correct Strategy in Frail Elderly Patients with Atrial Fibrillation and Acute Coronary Syndrome?","volume":"17","author":"Menditto","year":"2020","journal-title":"J. Geriatr. Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/europace\/eun369","article-title":"The Registry of the German Competence NETwork on Atrial Fibrillation: Patient Characteristics and Initial Management","volume":"11","author":"Nabauer","year":"2009","journal-title":"Europace"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.jacc.2020.08.001","article-title":"Direct Oral Anticoagulant Dosing: Truth or Consequences","volume":"76","author":"Naccarelli","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial Fibrillation Management: a Prospective Survey in ESC Member Countries: the Euro Heart Survey on Atrial Fibrillation","volume":"26","author":"Nieuwlaat","year":"2005","journal-title":"Eur. Heart J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A Novel User-Friendly Score (HAS-BLED) to Assess 1-year Risk of Major Bleeding in Patients with Atrial Fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"B26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for Dabigatran Reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/papr.12130","article-title":"Acetaminophen (Paracetamol) Oral Absorption and Clinical Influences","volume":"14","author":"Raffa","year":"2014","journal-title":"Pain Pract."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/ene.12180","article-title":"Impact of Blood Pressure Changes and Course on Hematoma Growth in Acute Intracerebral Hemorrhage","volume":"20","author":"Rodriguez-Luna","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: a Meta-Analysis of Randomised Trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12872-020-01509-x","article-title":"Concomitant Use of Direct Oral Anticoagulants and Aspirin versus Direct Oral Anticoagulants Alone in Atrial Fibrillation and Flutter: a Retrospective Cohort","volume":"20","author":"Said","year":"2020","journal-title":"BMC Cardiovasc. Disord."},{"key":"B31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.6061\/clinics\/2012(04)02","article-title":"Predictors of the Risk of Falls Among Elderly with Chronic Atrial Fibrillation","volume":"67","author":"Santos","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","article-title":"Effective and Safe Proton Pump Inhibitor Therapy in Acid-Related Diseases - A Position Paper Addressing Benefits and Potential Harms of Acid Suppression","volume":"14","author":"Scarpignato","year":"2016","journal-title":"BMC Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehn579","article-title":"Atrial Fibrillation in Acute Myocardial Infarction: a Systematic Review of the Incidence, Clinical Features and Prognostic Implications","volume":"30","author":"Schmitt","year":"2009","journal-title":"Eur. Heart J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1016\/S0049-3848(16)30113-X","article-title":"Management of Bleeding Complications in Patients with Cancer on DOACs","volume":"140","author":"Schulman","year":"2016","journal-title":"Thromb. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.amjmed.2015.10.001","article-title":"Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin","volume":"129","author":"Senoo","year":"2016","journal-title":"Am. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.jacc.2019.12.068","article-title":"Select Drug-Drug Interactions with Direct Oral Anticoagulants: JACC Review Topic of the Week","volume":"75","author":"Wiggins","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.str.22.8.983","article-title":"Atrial Fibrillation as an Independent Risk Factor for Stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"B40","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/ageing\/afv071","article-title":"Impact of Advanced Age on Management and Prognosis in Atrial Fibrillation: Insights from a Population-Based Study in General Practice","volume":"44","author":"Wolff","year":"2015","journal-title":"Age Ageing"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.769251\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T08:39:06Z","timestamp":1640162346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.769251\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,22]]},"references-count":41,"alternative-id":["10.3389\/fphar.2021.769251"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.769251","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,22]]},"article-number":"769251"}}